Candriam S.C.A. Acquires Shares of 47,191 Maximus, Inc. $MMS

Key Points

• Candriam S.C.A. acquired 47,191 shares of Maximus, Inc. worth approximately $3.2 million, which constitutes 0.08% of the company's total ownership.
• Maximus reported a quarterly EPS of $2.16, exceeding analysts' estimates, with a revenue of $1.35 billion, reflecting a 2.5% year-over-year increase.
• The company declared a quarterly dividend of $0.30, representing an annualized yield of 1.4%, set to be paid on August 31st.

Candriam S.C.A. purchased a new stake in Maximus, Inc. (NYSE:MMS - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 47,191 shares of the health services provider's stock, valued at approximately $3,218,000. Candriam S.C.A. owned approximately 0.08% of Maximus as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Fuller & Thaler Asset Management Inc. boosted its position in Maximus by 40.0% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,729,305 shares of the health services provider's stock valued at $117,921,000 after acquiring an additional 494,372 shares in the last quarter. SG Capital Management LLC bought a new stake in shares of Maximus during the fourth quarter valued at approximately $30,285,000. Reinhart Partners LLC. grew its stake in Maximus by 65.4% in the first quarter. Reinhart Partners LLC. now owns 911,511 shares of the health services provider's stock worth $62,156,000 after purchasing an additional 360,365 shares during the period. Boston Partners bought a new position in Maximus in the first quarter worth $20,983,000. Finally, Squarepoint Ops LLC bought a new stake in shares of Maximus during the 4th quarter valued at $22,661,000. 97.21% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on MMS. Wall Street Zen lowered shares of Maximus from a "buy" rating to a "hold" rating in a research note on Thursday, May 15th. Zacks Research upgraded Maximus from a "hold" rating to a "strong-buy" rating in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the stock. Based on data from MarketBeat, Maximus has an average rating of "Strong Buy" and a consensus price target of $90.00.

Insider Transactions at Maximus

In other news, Director Gayathri Rajan sold 7,913 shares of the firm's stock in a transaction dated Friday, May 30th. The shares were sold at an average price of $72.38, for a total transaction of $572,742.94. Following the sale, the director owned 14,205 shares of the company's stock, valued at $1,028,157.90. This trade represents a 35.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 1.60% of the company's stock.

Maximus Stock Down 0.3%

Shares of NYSE:MMS traded down $0.23 during trading on Thursday, reaching $87.33. 176,193 shares of the stock traded hands, compared to its average volume of 569,548. The stock has a market cap of $4.92 billion, a P/E ratio of 16.08 and a beta of 0.60. The company has a debt-to-equity ratio of 0.91, a quick ratio of 2.27 and a current ratio of 2.27. The stock has a 50-day moving average of $75.55 and a two-hundred day moving average of $71.38. Maximus, Inc. has a 52-week low of $63.77 and a 52-week high of $93.94.

Maximus (NYSE:MMS - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The health services provider reported $2.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.39 by $0.77. The business had revenue of $1.35 billion for the quarter, compared to analysts' expectations of $1.29 billion. Maximus had a return on equity of 24.44% and a net margin of 5.83%.The firm's quarterly revenue was up 2.5% on a year-over-year basis. During the same period in the prior year, the firm posted $1.74 EPS. Maximus has set its FY 2025 guidance at 7.350-7.550 EPS. As a group, sell-side analysts expect that Maximus, Inc. will post 6.15 earnings per share for the current fiscal year.

Maximus Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Sunday, August 31st. Shareholders of record on Friday, August 15th will be given a $0.30 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $1.20 dividend on an annualized basis and a yield of 1.4%. Maximus's payout ratio is 22.10%.

Maximus Company Profile

Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.